ONTRUZANT® (trastuzumab-dttb) for Injection, for Intravenous Use 21 mg/mL
Support and coverage

Remember, you are not alone.
Patient support for ONTRUZANT is available.

Patient Support for ONTRUZANT® (trastuzumab-dttb) Is Available Not an actual patient.

The Organon Access Program for ONTRUZANT

The Organon Access Program (OAP) may be able to answer your questions about insurance coverage, co-pay assistance for eligible patients, eligibility determination, and more. You can:

Speak to A Representative By Calling 844-326-2986

Speak to a
by calling

Learn About Options for Co-Pay Assistance for Eligible Patients

Learn about
options for co-pay
assistance for
eligible patients

Find Out About Insurance Coverage for ONTRUZANT® (trastuzumab-dttb) Costs, Including Any Out-of-Pocket Costs

Find out about insurance
coverage for ONTRUZANT
costs, including any
out-of-pocket costs


ONTRUZANT treatment can result in heart problems. Serious and sometimes fatal events have occurred. Some patients have had serious and fatal infusion reactions and lung problems. Symptoms usually occur during or within 24 hours of administration. ONTRUZANT can cause harm to an unborn baby, in some cases death of the unborn baby, when taken by a pregnant woman. ONTRUZANT treatment may lead to a worsening of low white blood cell count.